Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Operating Expenses: 2009-2024

Historic Operating Expenses for Tg Therapeutics (TGTX) over the last 16 years, with Dec 2024 value amounting to $287.1 million.

  • Tg Therapeutics' Operating Expenses rose 85.24% to $132.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $429.1 million, marking a year-over-year increase of 61.75%. This contributed to the annual value of $287.1 million for FY2024, which is 34.76% up from last year.
  • Latest data reveals that Tg Therapeutics reported Operating Expenses of $287.1 million as of FY2024, which was up 34.76% from $213.0 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Operating Expenses ranged from a high of $351.5 million in FY2021 and a low of $213.0 million during FY2023.
  • Over the past 3 years, Tg Therapeutics' median Operating Expenses value was $221.1 million (recorded in 2022), while the average stood at $240.4 million.
  • As far as peak fluctuations go, Tg Therapeutics' Operating Expenses spiked by 61.78% in 2020, and later slumped by 37.09% in 2022.
  • Over the past 5 years, Tg Therapeutics' Operating Expenses (Yearly) stood at $273.7 million in 2020, then increased by 28.39% to $351.5 million in 2021, then plummeted by 37.09% to $221.1 million in 2022, then dropped by 3.65% to $213.0 million in 2023, then spiked by 34.76% to $287.1 million in 2024.